Skip to content

Open-Label Placebo Treatment for Acute Postoperative Pain

Open-Label Placebo Treatment for Acute Postoperative Pain: A Randomized Controlled Trial (OLP-POP Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04339023
Acronym
OLP-POP
Enrollment
76
Registered
2020-04-08
Start date
2020-05-12
Completion date
2023-01-31
Last updated
2023-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

postoperative pain, Open-Label Placebo, morphine, Transforaminal Lumbar Interbody Fusion

Brief summary

This study is to evaluate whether the amount of morphine intake in acute postoperative pain following minimally invasive Transforaminal Lumbar Interbody Fusion (TLIF) can be decreased with an Open-Label Placebo (OLP) intervention (comprising the administration of sodium chloride (NaCl) injections and an evidence-based treatment rationale) in comparison to a Treatment As Usual (TAU) control group.

Interventions

in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)

OTHERtreatment as usual

usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed Informed Consent * Scheduled to receive a TLIF procedure at University Hospital Basel (USB) * 18 years or older * German speaking * Able to understand the study and its outcome measures

Exclusion criteria

* Known chronic pain, which is unrelated to problem targeted by the surgery * Known neuromuscular disease * Known mental disorders * Known drug or massive alcohol intake or of other psychoactive substances * Known kidney or liver disease (glomerular filtration rate (GFR)/ GFR \< 30) * Contraindications to the class of drugs under investigation, e.g., known hypersensitivity or allergy to the investigational product * Parallel participation in another study with investigational drugs * More than 30 mg/day (equivalent dose of oral morphine) preoperative opioid consumption

Design outcomes

Primary

MeasureTime frameDescription
Difference in morphine consumptionstarting on the first day post-surgery at 09:00 am (T1) and ending on the third day of surgery at 09:00 am (T5). morphine records will be read out twice a day (9:00 am and 16:45)cumulative dose (i.e., total amount) of self-administered morphine within 48 hours starting on the first day post-surgery at 09:00 am (T1) and ending on the third day of surgery at 09:00 am (T5)

Secondary

MeasureTime frameDescription
Difference in pain intensity at restThe two at rest scales (for leg and back pain) will be administered every two hours starting after transport to normal ward on the day of surgery (T0) until 09:00 am on the third day post-surgery (T5) and as well before surgery (T-1)back and leg pain intensity at rest will be measured separately by two 11-point Numeric Rating Scales (NRS, i.e., back / leg pain intensity at rest), which assesses pain intensity by asking participants to rate their pain intensity on a 0 to 10 scale, where 0 is no pain and 10 is worst pain possible
Difference in pain intensity while walkingThe two while walking scales will be administered the day before surgery (T-1), after transport to normal ward (i.e., at T0), at T2 (16:45, 1st day after surgery), T4 (16:45 2nd day post surgery), respectively.back and leg pain intensity while walking will be measured separately by two 11-point Numeric Rating Scales (i.e., back / leg pain intensity while walking), which assesses pain intensity by asking participants to rate their pain intensity on a 0 to 10 scale, where 0 is no pain and 10 is worst pain possible
Difference in comprehensive pain assessment and patients' perception of postoperative pain managementThe scale will be administered on the day before surgery (T-1), in the morning of the first day post-surgery (i.e., between 07:00 and 09:00; T0) , after the pain nurse visit 09:00 am day 2 (T3) and 09:00 am day 3 (T5) post-surgerywill be assessed by the German version of the International Pain Outcomes (IPO) Questionnaire. The IPO assesses patients pain experience and outcomes regarding patient reported aspects
Difference in morphine request ratesbetween T1 (9:00 am day post surgery) and T5 (9:00 am, 3rd day post surgery) (48 hours, morphine records will be read out twice a day (9:00 am and 16:45)Morphine demand behaviour will be measured by the total number of successful and unsuccessful clicks on the Patient Controlled Analgesia (PCA) pump between T1 and T5 (48 hours)
Opioid-Related Side EffectsAfter trial completion of participants, study team members will extract the data from hospital records for the time periods of: the day of surgery (T0) till first day post-surgery at 09:00 am (T1) and T1 to T5 (09:00 am day 3 post-surgery)nausea, vomiting and constipation (i.e., stool frequency, vomiting and amount of delivered laxatives and antiemetics) are regularly assessed and documented as part of standard hospital procedures
Length of Post-Surgery HospitalisationLength of Post-Surgery Hospitalisation, approximately 14 days after surgeryLength of Post-Surgery Hospitalisation, upon participants trial completion this data will be extracted by study team members from the electronic hospital record of each patient
Difference in requested rescue analgesicsAfter trial completion of participants, study team members will extract the data from hospital records for the time periods of: the day of surgery (T0) till first day post-surgery at 09:00 am (T1) and T1 to T5 (09:00 am day 3 post-surgery)will be regularly assessed as part of standard procedures of the hospital and will be documented in the electronic hospital record of each patient

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026